文献速递胸部肿瘤

依沃西单抗联合化疗对比安慰剂联合化疗治疗EGFR突变晚期NSCLC的3期试验

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

HARMONi研究纳入438例第三代EGFR-TKI治疗后进展的EGFR突变晚期非鳞NSCLC患者,随机接受依沃西单抗或安慰剂联合培美曲塞和卡铂。安全性总体可控。

要点

  • 常见3-4级治疗相关不良事件为中性粒细胞减少等。

核心结论

  • 依沃西单抗联合化疗在EGFR-TKI治疗后进展的EGFR突变NSCLC中显示有临床意义且统计学显著的PFS获益。

研究设计与样本

  • HARMONi为多中心、随机、双盲、安慰剂对照3期试验,在亚洲、欧洲和北美114个中心进行。
  • 共筛查660例,入组438例,按1:1随机分配至依沃西单抗联合化疗组或安慰剂联合化疗组(每组219例)。
  • 主要终点为盲法独立影像评估的PFS和意向治疗人群的OS。

主要发现

  • 最常见的3-4级治疗相关不良事件:中性粒细胞计数减少(依沃西单抗组42/218[19%] vs 安慰剂组36/218[17%])、白细胞计数减少(28[13%] vs 24[11%])、血小板计数减少(27[12%] vs 14[6%])、贫血(22[10%] vs 27[12%])。
  • 严重治疗相关不良事件发生在依沃西单抗组61例(28%)和安慰剂组33例(15%)。
  • 治疗相关不良事件导致死亡:依沃西单抗组4例(疾病进展、多器官功能障碍综合征、肝衰竭各1例,另1例为消化道出血和肺栓塞),安慰剂组5例(肺炎、心肌梗死、脑血管意外、认知障碍、栓塞性卒中各1例)。

临床怎么用

  • 对于第三代EGFR-TKI治疗后进展的EGFR突变晚期非鳞NSCLC患者,依沃西单抗联合培美曲塞和卡铂可作为新的治疗选择。

局限性

  • 研究未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ivonescimab has shown clinical efficacy in non-small-cell lung cancer (NSCLC). We aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy. METHODS: HARMONi is a randomised, placebo-controlled, double-blind, phase 3 trial done at 114 cancer centres and hospitals across Asia, Europe, and North America. Eligible patients were aged at least 18 years (upper limit: 75 years in Asia) with stage IIIB/IIIC or IV non-squamous EGFR-mutated NSCLC, disease progression after treatment with a third-generation EGFR-TKI, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. Patients were randomly assigned (1:1) via a centralised interactive voice response system or interactive web response system to receive ivonescimab (20 mg/kg) or placebo plus pemetrexed (500 mg/m2) and carboplatin (target area under the curve 5 mg/mL per min) intravenously every 3 weeks. Randomisation was stratified by brain metastases status at enrolment and geographical region. The primary endpoints were progression-free survival by blinded independent radiology review committee and overall survival in the intention-to-treat population. Safety was assessed in patients who received at least one dose of trial treatment. This study is registered with ClinicalTrials.gov (NCT06396065), has completed enrolment, and is ongoing for treatment and follow-up. FINDINGS: From Jan 25, 2022, to Oct 1, 2024, 660 individuals were screened for eligibility; of these, 438 were enrolled and randomly assigned to receive ivonescimab plus chemotherapy or placebo plus chemotherapy (219 per group). Of enrolled patients, 257 (59%) were female and 181 (41%) were male; 306 (70%) reported race as Asian, and 105 (24%) as White. At a median follow-up of 22·3 months (95% CI 21·5-23·0), 275 progression or death events had occurred in 345 patients (129 events among 172 patients in the ivonescimab plus chemotherapy group and 146 events among 173 patients in the placebo plus chemotherapy group). Median progression-free survival was 6·8 months (95% CI 5·7-7·1) in the ivonescimab plus chemotherapy group versus 4·4 months (4·1-5·5) in the placebo plus chemotherapy group (hazard ratio [HR] 0·52; 95% CI 0·41-0·66; p<0·0001). At a median follow-up of 29·7 months (95% CI 27·7-31·0), 262 deaths occurred in 438 patients (122 in the ivonescimab plus chemotherapy group and 140 in the placebo plus chemotherapy group). Median overall survival was 16·8 months (14·3-19·0) in the ivonescimab plus chemotherapy group versus 14·0 months (12·8-15·7) in the placebo plus chemotherapy group (HR 0·79; 0·62-1·01). The most common grade 3-4 treatment-related adverse events in the ivonescimab plus chemotherapy versus the placebo plus chemotherapy group were decreased neutrophil count (42 [19%] of 218 vs 36 [17%] of 218), decreased white blood cell count (28 [13%] vs 24 [11%]), decreased platelet count (27 [12%] vs 14 [6%]), and anaemia (22 [10%] vs 27 [12%]). Serious treatment-related adverse events occurred in 61 (28%) patients in the ivonescimab plus chemotherapy group and 33 (15%) patients in the placebo plus chemotherapy group. Treatment-related adverse events led to death in four patients (disease progression, multiple organ dysfunction syndrome, and hepatic failure, each in one patient; gastrointestinal haemorrhage and pulmonary embolism in one patient) in the ivonescimab plus chemotherapy group and five patients (pneumonitis, myocardial infarction, cerebrovascular accident, cognitive disorder, and embolic stroke, each in one patient) in the placebo plus chemotherapy group. INTERPRETATION: Ivonescimab plus chemotherapy showed a clinically meaningful and statistically significant progression-free survival benefit in patients with EGFR-mutated NSCLC after progression on EGFR-TKI therapy. The clinical benefit and lack of new safety signals of ivonescimab with chemotherapy support the potential for the combination as a new treatment option in this patient population. FUNDING: Summit Therapeutics.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Le X, Passaro A, Zhao Y, et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026. PMID: 42636833. doi:10.1016/S1470-2045(26)00282-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。